1. LIM Domain Only-2 (LMO2) Induces T-Cell Leukemia by Two Distinct Pathways.
- Author
-
Smith, Stephen, Tripathi, Rati, Goodings, Charnise, Cleveland, Susan, Mathias, Elizabeth, Hardaway, J. Andrew, Elliott, Natalina, Yi, Yajun, Chen, Xi, Downing, James, Mullighan, Charles, Swing, Deborah A., Tessarollo, Lino, Li, Liqi, Love, Paul, Jenkins, Nancy A., Copeland, Neal G., Thompson, Mary Ann, Du, Yang, and Davé, Utpal P.
- Subjects
LEUKEMIA treatment ,T cells ,ONCOGENES ,GENE therapy ,TRANSGENIC mice ,GENE expression ,CD2 antigen ,PROMOTERS (Genetics) - Abstract
The LMO2 oncogene is deregulated in the majority of human T-cell leukemia cases and in most gene therapy-induced T-cell leukemias. We made transgenic mice with enforced expression of Lmo2 in T-cells by the CD2 promoter/enhancer. These transgenic mice developed highly penetrant T-ALL by two distinct patterns of gene expression: one in which there was concordant activation of Lyl1, Hhex, and Mycn or alternatively, with Notch1 target gene activation. Most strikingly, this gene expression clustering was conserved in human Early T-cell Precursor ALL (ETP-ALL), where LMO2, HHEX, LYL1, and MYCN were most highly expressed. We discovered that HHEX is a direct transcriptional target of LMO2 consistent with its concordant gene expression. Furthermore, conditional inactivation of Hhex in CD2-Lmo2 transgenic mice markedly attenuated T-ALL development, demonstrating that Hhex is a crucial mediator of Lmo2's oncogenic function. The CD2-Lmo2 transgenic mice offer mechanistic insight into concordant oncogene expression and provide a model for the highly treatment-resistant ETP-ALL subtype. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF